NKTR - ネクタ―・セラピュ―ティクス (Nektar Therapeutics) ネクタ―・セラピュ―ティクス

 NKTRのチャート


 NKTRの企業情報

symbol NKTR
会社名 Nektar Therapeutics (ネクタ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ネクター・セラピューティクス(Nektar Therapeutics)は医薬品を発見・開発するバイオ医薬品企業である。同社の新規治験薬の研究開発パイプラインには、がん、自己免疫疾患、慢性疼痛の治療が含まれる。同社は化学物質のプラットフォームを活用して新薬の候補を発見・設計する。薬物候補は既知の作用機序を標的とする新しい分子実体の開発を可能にするように設計されたポリマーコンジュゲート技術プラットフォームを利用する。同社のプログラムには、免疫腫瘍学(I-O)、免疫学、Pain-NKTR-181、および腫瘍学ONZEALDが含まれる。同社は細胞傷害性T細胞やナチュラルキラー(NK)細胞などの主要な免疫細胞の活性を直接的または間接的に調節してその数を増やし、癌細胞を認識して攻撃する機能を改善するように設計された医薬品を開発する。   ネクタ―・セラピュ―ティクスは、米国の医薬品開発会社。PEG化と高度なポリマ―接合体技術プラットフォ―ムを利用し、薬剤を開発。同社の薬剤候補ナロキセゴ―ルは、オピオイド誘発性便秘の治療に使われる経口末梢性オピオイド拮抗薬で、非癌性疼痛をもつ患者に使われる。その他、「Etirinotecanペゴル」、「NKTR-181」などがある。   Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.
本社所在地 455 Mission Bay Boulevard South San Francisco CA 94158 USA
代表者氏名 Robert B. Chess ロバートB.チェス
代表者役職名 Independent Chairman of the Board
電話番号 +1 415-482-5300
設立年月日 33055
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 509人
url www.nektar.com
nasdaq_url https://www.nasdaq.com/symbol/nktr
adr_tso
EBITDA EBITDA(百万ドル) 959.86200
終値(lastsale) 51.79
時価総額(marketcap) 8932157753.67
時価総額 時価総額(百万ドル) 8261.254
売上高 売上高(百万ドル) 1374.129
企業価値(EV) 企業価値(EV)(百万ドル) 6683.524
当期純利益 当期純利益(百万ドル) 902.71300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Nektar Therapeutics revenues increased from $59.3M to $1.13B. Net income totaled $875.7M vs. loss of $123.7M. Revenues reflect License collaboration and other increase from $10.9M to $1.08B Royalty revenue increase of 34% to $19.6M Non-cash royalty revenue related to sale increase of 20% to $16M. Net Income reflects Other income (expense) net increase from $1.6M to $13.7M (income).

 NKTRのテクニカル分析


 NKTRのニュース

   RedHill Biopharma Says Resolves Movantik Patent Litigation With Aurobindo  2021/09/23 12:05:10 Business Insider Markets
(RTTNews) - RedHill Biopharma Ltd. (RDHL), a specialty biopharmaceutical company, on Thursday, said RedHill Biopharma Inc., AstraZeneca AB, AstraZeneca Pharmaceuticals LP, and Nektar Therapeutics have entered into a settlement and license deal with Aurobindo Pharma USA, Inc. to resolve their patent litigation in the U.S. The latest move of the
   Nektar Therapeutics enters oncology clinical collaboration with Merck KGaA and Pfizer  2021/09/21 13:12:28 Seeking Alpha
   Bristol-Myers Squibb Company Consensus Indicates Potential 31.0% Upside  2021/09/20 09:42:34 DirectorsTalk
Bristol-Myers Squibb Company with ticker code (BMY) have now 17 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 144 and 66 and has a mean target at 80.24. Given that the stocks previous close was at 61.23 this would imply there is a potential upside of 31.0%. The 50 day moving average now sits at 66.42 and the 200 day MA is 65.36. The company has a market capitalisation of $136,238m. Company Website: /> [stock_market_widget type="chart" symbol="BMY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
   Bristol-Myers Squibb Company Consensus Indicates Potential 15.6% Upside  2021/08/30 16:31:40 DirectorsTalk
Bristol-Myers Squibb Company with ticker code (BMY) now have 17 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 94 and 66 calculating the average target price we see 77.01. Now with the previous closing price of 66.6 this would indicate that there is a potential upside of 15.6%. The 50 day MA is 67.84 and the 200 day MA is 65.04. The market capitalisation for the company is $148,837m. Find out more information at: /> [stock_market_widget type="chart" symbol="BMY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
   Non-Hodgkin''s Lymphoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline  2021/08/27 00:00:00 Benzinga
Los Angeles, USA, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Non-Hodgkin''s Lymphoma Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Increasing awareness about the condition, improved diagnostic techniques and a robust drug pipeline promises a better future Non-Hodgkin''s Lymphoma Space Outlook. DelveInsight''s Non-Hodgkin''s Lymphoma (NHL) Pipeline Insights '' report lays down a holistic coverage of the available therapies, Non-Hodgkin''s Lymphoma pipeline therapies in different phases of clinical development, key companies active in the NHL pipeline domain, drivers and barriers in the successful launch of the therapies and future trends. Some of the notable pointers extracted from the Non-Hodgkin''s Lymphoma Pipeline report: DelveInsight''s analysis depicts a robust Non-Hodgkin''s Lymphoma Pipeline with 150+ active players in the domain working on 150+ pipeline therapies . Key Non-Hodgkin''s Lymphoma pipeline therapies such as Obinutuzumab, Abemaciclib, Ibrutinib, CPI 818, Devimistat, Venetoclax, Loncastuximab tesirine, LAM-002, HMPL-523, Venetoclax, Ibrutinib, Naratuximab emtansine, NKTR-255, LOXO-305, LAM002, CNCT19, GB226, BI-1206, CAR-CD19 T Cells, AUTO4, TT11, CC-99282, AB-205 and others are under investigation in different phases of clinical trials for the treatment of Non-Hodgkin''s Lymphoma.
   Gram-Negative Bacterial Infection Market - Development Assessment 2025 | Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd.  2021/06/18 08:12:39 OpenPR
Global Gram-Negative Bacterial Infection Market: Snapshot Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due
   Natural Killer Cell Therapy Market by Growth Analysis (2020-2026) | Nektar Therapeutics, Innate Pharma SA, Affimed  2021/06/14 10:45:12 Jumbo News
QYResearch Published Global Natural Killer Cell Therapy Market Research Report 2020: Industry Growth, Opportunities, Vendors, Shares, Competitive Strategies And Forecasts 2026. Los Angeles, United State The report on the global Natural Killer Cell Therapy market is a compilation of intelligent, broad research studies that will help players and stakeholders to make informed business decisions in []
   Nano-Medical Device Market 2021 Emerging Trends and Growth Analysis Till 2028 | Affymetrix, Crucell N.V., Flamel Technologies S.A., Nektar Therapeutics, Par Pharmaceutical companies Inc & More  2021/06/12 09:00:00 iCrowdNewswire
Worldwide Nano-Medical Device Market Analysis to 2028 is a specialized and in-depth study of the Nano-Medical Device Market Industry with a focus on the global market trend. The report aims []
   Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference  2021/06/07 00:00:00 BioSpace
Nektar Therapeutics'' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time .
   Bristol-Myers Squibb Company Consensus Indicates Potential 14.7% Upside  2021/05/31 11:09:16 DirectorsTalk
Bristol-Myers Squibb Company with ticker code (BMY) have now 17 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 90 and 62 calculating the mean target price we have 75.37. Given that the stocks previous close was at 65.71 this now indicates there is a potential upside of 14.7%. There is a 50 day moving average of 65.15 and the 200 moving average now moves to 62.94. The market capitalisation for the company is $146,742m. Find out more information at: /> [stock_market_widget type="chart" symbol="BMY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.
   Gram-Negative Bacterial Infection Market - Development Assessment 2025 | Nektar Therapeutics, Dainippon Sumitomo Pharma Co., Ltd.  2021/06/18 08:12:39 OpenPR
Global Gram-Negative Bacterial Infection Market: Snapshot Worldwide, antimicrobial resistance is a soaring concern for a range of diseases, especially for enteric fever, respiratory tract infections, and various infections related with gram-negative bacilli (GNB). An upsurge in antibiotic resistance is mainly due
   Natural Killer Cell Therapy Market by Growth Analysis (2020-2026) | Nektar Therapeutics, Innate Pharma SA, Affimed  2021/06/14 10:45:12 Jumbo News
QYResearch Published Global Natural Killer Cell Therapy Market Research Report 2020: Industry Growth, Opportunities, Vendors, Shares, Competitive Strategies And Forecasts 2026. Los Angeles, United State The report on the global Natural Killer Cell Therapy market is a compilation of intelligent, broad research studies that will help players and stakeholders to make informed business decisions in []
   Nano-Medical Device Market 2021 Emerging Trends and Growth Analysis Till 2028 | Affymetrix, Crucell N.V., Flamel Technologies S.A., Nektar Therapeutics, Par Pharmaceutical companies Inc & More  2021/06/12 09:00:00 iCrowdNewswire
Worldwide Nano-Medical Device Market Analysis to 2028 is a specialized and in-depth study of the Nano-Medical Device Market Industry with a focus on the global market trend. The report aims []
   Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference  2021/06/07 00:00:00 BioSpace
Nektar Therapeutics'' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time .
   Bristol-Myers Squibb Company Consensus Indicates Potential 14.7% Upside  2021/05/31 11:09:16 DirectorsTalk
Bristol-Myers Squibb Company with ticker code (BMY) have now 17 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 90 and 62 calculating the mean target price we have 75.37. Given that the stocks previous close was at 65.71 this now indicates there is a potential upside of 14.7%. There is a 50 day moving average of 65.15 and the 200 moving average now moves to 62.94. The market capitalisation for the company is $146,742m. Find out more information at: /> [stock_market_widget type="chart" symbol="BMY" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ネクタ―・セラピュ―ティクス NKTR Nektar Therapeutics)

 twitter  (公式ツイッターやCEOツイッターなど)